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Abstract: To test the hypothesis that p38α-MAPK plays a critical role in the regulation of E3 ligase
expression and skeletal muscle atrophy during unloading, we used VX-745, a selective p38α inhibitor.
Three groups of rats were used: non-treated control (C), 3 days of unloading/hindlimb suspension (HS),
and 3 days HS with VX-745 inhibitor (HSVX; 10 mg/kg/day). Total weight of soleus muscle in HS group
was reduced compared to C (72.3 ± 2.5 vs 83.0 ± 3 mg, respectively), whereas muscle weight in the
HSVX group was maintained (84.2 ± 5 mg). The expression of muscle RING-finger protein-1 (MuRF1)
mRNA was significantly increased in the HS group (165%), but not in the HSVX group (127%), when
compared with the C group. The expression of muscle-specific E3 ubiquitin ligases muscle atrophy
F-box (MAFbx) mRNA was increased in both HS and HSVX groups (294% and 271%, respectively)
when compared with C group. The expression of ubiquitin mRNA was significantly higher in the
HS (423%) than in the C and HSVX (200%) groups. VX-745 treatment blocked unloading-induced
upregulation of calpain-1 mRNA expression (HS: 120%; HSVX: 107%). These results indicate that
p38α-MAPK signaling regulates MuRF1 but not MAFbx E3 ligase expression and inhibits skeletal
muscle atrophy during early stages of unloading.
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1. Introduction
Skeletal muscle has a large amount of plasticity, responding to the decrease in activity caused
by a variety of conditions (immobilization, microgravity, prolonged bed rest, denervation, etc.) by
atrophy, declined muscle fiber diameter, loss of protein content, decreased specific force, and increased
fatigability [1–3]. Skeletal muscle atrophy is caused by accelerated protein degradation and decreased
protein synthesis [4,5]. In order to prevent muscle atrophy, it is critically important to understand the
molecular mechanisms regulating the initiation of muscle atrophy. The expression of muscle-specific
E3 ubiquitin ligases muscle atrophy F-box (MAFbx) and muscle RING-finger protein-1 (MuRF1) is
regulated via activity of the ubiquitin–proteasome pathway. The majority of previous studies focused
on the role of Forkhead box protein O (FoxO) phosphorylation/de-phosphorylation by Akt in the
regulation of E3 ubiquitin ligase expression [6]. Nevertheless, our previous studies showed that during
unloading FoxO3 and NF-κB pathways do not inevitably control the upregulation of MuRF1 [7–9].
In some instances, different regulatory mechanisms can play the most critical role in the regulation of
MuRF1 expression.
It was previously reported that denervation-induced decrease in skeletal muscle mass is regulated
via p38αMAP kinase signaling [10]. However, it is not well defined as to whether this signaling pathway
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also participates in the unloading-induced upregulation of E3 ubiquitin ligases and in the onset of skeletal
muscle atrophy. There are three major MAP kinase signaling pathways regulated via phosphorylation:
extracellular signal-related kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 MAP kinase. p38
MAP kinase plays a major role in the regulation of transcription and in cell motility [11,12]. Only
a few studies have looked at the role of p38 MAP kinase during unloading. It was reported that
unloading-increased activation of p38 MAP kinase correlated with skeletal muscle atrophy [13,14].
Activation of MAP kinase regulates proliferation and differentiation via phosphorylation of cytoplasmic
and nuclear proteins, as well as modulation of gene expression [14]. Dupont and colleagues suggested
that increased phosphorylation of p38 MAP kinase after 14 days of unloading can be involved in the
regulation of myosin heavy chain expression and unloading-induced changes in myosin composition [14].
It was previously reported that unloading-induced activation of p38 MAP kinase participates in the
initiation of protein degradation [15]. Inhibition of p38 MAP kinase activity in cultured muscle cells
using SB203580, an inhibitor of p38 MAP kinase, or curcumin decreased activity of ubiquitin. Therefore,
p38 MAP kinase may be involved in the regulation of the ubiquitin–proteasome pathway.
Increased expression of E3 ubiquitin ligases during unloading can be detected at the first day,
and it peaks by the third day [16]. However, previous studies investigated later time points in p38 MAP
kinase activation during unloading. The only exception is the study by Kawamoto and colleagues that
showed increased p38 MAP kinase phosphorylation at 6 hours after unloading of rat soleus muscle [17].
Expression of E3 ubiquitin ligases was not tested in this study.
In the current study, we examined whether activation of p38α MAP kinase at the early stages
of unloading regulated the expression of muscle-specific E3 ubiquitin ligases MAFbx and MuRF1.
We used VX-745, a specific inhibitor of p38α MAP kinase, and tested its effect on the regulation of the
ubiquitin–proteasome pathway and on skeletal muscle atrophy during unloading. We hypothesized
that blocking of p38α MAP kinase activation will prevent the upregulation of E3 ubiquitin ligases and
muscle atrophy during early stages of unloading.
2. Results
2.1. The Effect of VX-745 Treatment on Muscle Atrophy and Unloading-Induced Protein Degradation Pathways
in Rat Soleus Muscle
To evaluate the effectiveness of VX-745 inhibitor in our experiments, we first determined the level
of p38 phosphorylation in soleus muscles of non-treated control (C), 3 days of unloading/hindlimb
suspension (HS), and 3 days HS with VX-745 inhibitor (HSVX) rats (Figure 1). Unloading significantly
increased the content of phospho-p38 (Figure 1). This increase was blocked by VX-745 treatment (Figure 1).
These results confirm the specificity and effectiveness of VX-745 inhibitor in our experimental conditions.
Three days of unloading had no statistically significant effect on the total body weight of the
experimental rats. The average total body weights were 200 ± 13.5, 186 ± 9.97, and 195 ± 12.9 g for C,
HS, and HSVX rats, respectively. Treatment with VX-745 prevented unloading-induced soleus muscle
atrophy (Figure 2). VX-745 treatment blocked decrease of both absolute soleus muscle mass (Figure 2A)
as well as soleus muscle mass normalized to the total body weight (Figure 2B).
It is known that, during unloading, calpain-1 and ubiquitin are involved in skeletal muscle
protein degradation [9]. As expected, unloading significantly increased calpain-1 mRNA expression,
whereas VX-745 treatment blocked this increase (Figure 3A). Similarly, VX-745 treatment diminished
unloading-induced upregulation of the ubiquitin mRNA expression (Figure 3B).
VX-745 treatment differently affected the expression of two skeletal muscle-specific E3 ligases
MuRF1 and MAFbx. VX-745 treatment had no effect on the unloading-induced increase in mRNA
expression of MAFbx (Figure 4A). At the same time, it significantly diminished the unloading-induced
increase in mRNA (Figure 4B) and protein (Figure 4C) expression of MuRF1.
It was previously reported that upon muscle unloading, changes in Akt1, FoxO3 [9], and PGC-1α [18]
signaling promote protein degradation via induced expression of the muscle-specific ubiquitin ligases
MuRF1 and MAFbx. VX-745 treatment had no effect on the unloading-induced decrease in phospho-Akt
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content (Figure 5A). At the same time, VX-745 treatment blocked unloading-induced decrease in
phospho-FoxO3 content (Figure 5B). VX-745 prevented unloading-induced decrease in PGC-1α, and even
showed a trend towards PGC-1α content increase when compared with the control muscle (Figure 6).
PGC-1α expression is regulated by IL-6 signaling [19]. To test whether increased expression of
PGC-1α in the HSVX group correlates with increased IL-6 expression in muscle, we evaluated mRNA
expression of IL-6 and IL-6 receptor. In the HS group, expression of both IL-6 and IL-6 receptor were
significantly increased (Figure 7). VX-745 treatment blocked unloading-induced IL-6 upregulation, but
had no effect on the increased expression of IL-6 receptor (Figure 7).
Figure 1. Evaluation of phospho-p38 content in soleus muscles of non-treated control (C), 3 days of
unloading/hindlimb suspension (HS), and 3 days HS with VX-745 inhibitor (HSVX) rats by Western
blotting. Values are normalized to the levels of total protein and total-p38 expression in each sample.
n = 8. * indicates a significant difference from the control, p < 0.05; # indicates a significant difference
from the HS, p < 0.05.
Figure 2. Absolute (A) and normalized (B) weight of soleus muscles of C, HS, and HSVX rats. n = 8.
* indicates a significant difference from the control, p < 0.05, # indicates a significant difference from the
HS, p < 0.05.
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Figure 3. Evaluation of mRNA expression of calpain-1 (A) and ubiquitin (B) in soleus muscles of C,
HS, and HSVX rats. Values are normalized to the level of GAPDH mRNA expression in each sample.
n = 8. * indicates a significant difference from the control, p < 0.05; # indicates a significant difference
from the HS, p < 0.05.
Figure 4. Expression of muscle-specific E3 ubiquitin ligases muscle atrophy F-box (MAFbx) mRNA (A)
and muscle RING-finger protein-1 (MuRF1) mRNA (B) and protein (C) in soleus muscles of C, HS,
and HSVX rats. (A,B) Values are normalized to the level of GAPDH mRNA expression in each sample.
(C) Values are normalized to the levels of total protein and GAPDH protein content in each sample.
n = 8. * indicates a significant difference from the control, p < 0.05; # indicates a significant difference
from the HS, p < 0.05.
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Figure 5. Evaluation of phospho-Akt (A) and phospho-FoxO3 (B) content in soleus muscles of C, HS,
and HSVX rats by Western blotting. Values are normalized to the levels of total protein and total Akt or
GAPDH content in each sample. n = 8. * indicates a significant difference from the control, p < 0.05;
# indicates a significant difference from the HS, p < 0.05.
Figure 6. Evaluation of PGC-1α protein expression in soleus muscles of C, HS, and HSVX rats by Western
blotting. Values are normalized to the level of GAPDH content in each sample. n = 8. # indicates a
significant difference from the HS, p < 0.05.
Figure 7. Evaluation of mRNA expression of IL-6 (A) and IL-6 receptor (B) in soleus muscles of C, HS,
and HSVX rats. Values are normalized to the level of GAPDH mRNA in each sample. n = 8. * indicates a
significant difference from the control, p < 0.05; # indicates a significant difference from the HS, p < 0.05.
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2.2. The Effect of VX-745 Treatment on Protein Synthesis Pathways in Rat Soleus Muscle
Unloading-induced muscle atrophy is regulated not only via accelerated protein degradation but
also by decreased protein synthesis. Therefore, we evaluated the effect of VX-745 treatment on the
protein synthesis during unloading. Levels of phospho-p70S6K were significantly increased in both
HS and HSVX groups when compared with the control (Figure 8A). Levels of phospho-4EBP were not
significantly changed by the unloading or VX-745 treatment (Figure 8B). Levels of phospho-eEF2 were
significantly increased in both HS and HSVX groups when compared with the control (Figure 8C).
These results suggest that p38 signaling is not involved in the regulation of the unloading-induced
p70S6K, 4EBP, and eEF2 phosphorylation.
Figure 8. Evaluation of phospho-p70S6K (A), phospho-4EBP1 (B), and phospho-eEF2 (C) content in
soleus muscles of C, HS, and HSVX rats by Western blotting. Values are normalized to the levels of
total protein and total p70S6K, 4E-BP1, and eEF2 content in each sample. n = 8. * indicates a significant
difference from the control, p < 0.05.
3. Discussion and Conclusions
Unloading-induced skeletal muscle atrophy is a complex process. The molecular mechanisms
involved in the regulation of the early stages of muscle atrophy are not well defined. Our study focused
on the role of p38α MAP kinase in the regulation of early stages of unloading-induced muscle atrophy.
During initial stages of the study, we verified that VX-745 potently and specifically inhibited
p38α MAP kinase under our experimental conditions. VX-745 inhibitor was highly specific for the
p38α MAPK and it had minimal effects on other kinases. The majority of the previous publications
used SB202190 p38 MAPK inhibitor [20,21]. Different to SB202190, VX-745 is a more potent inhibitor
with an IC50 of 10 nM. SB203850 has an IC50 of 300–500 nM. Moreover, it was recently reported that
SB202190 should not be used in research studies as an inhibitor of p38 MAPK due to its action on
the autophagy–lysosomal axis [22]. Using a highly specific inhibitor, the current study showed that
unloading-induced p38α MAP kinase phosphorylation was significantly reduced in the presence of
VX-745 inhibitor.
The current study demonstrated that by inhibiting p38α MAP kinase phosphorylation, we were
able to block unloading-induced muscle atrophy. Both absolute weight of soleus muscle and total
body weight-adjusted weight of soleus muscle were decreased by unloading, and these decreases
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were blocked by the VX-745 treatment. It is well documented that early stages of unloading induce
skeletal muscle atrophy [23], and that muscle atrophy is especially pronounced at the later stages of
unloading [14,24]. Yuasa and colleagues previously showed that muscle-specific ablation of p38α
MAP kinase diminished denervation-induced skeletal muscle atrophy [10]. The effect of p38α MAP
kinase on calpains and ubiquitin-proteasome pathway was not evaluated in that study [10]. Total body
weight was not statistically different in C, HS, and HSVX groups in our study. This suggests that 3 days
of unloading do not have a significant effect on the total body weight. Moreover, it was previously
reported that the weight of the soleus muscle is not affected by 2 days of fasting [25]. Therefore, a
significant decrease of soleus muscle weight in the unloaded rats in our study was not affected by the
food intake.
We previously showed that calpain-dependent breakdown of cytoskeletal proteins plays a critical
role during early stages of unloading-induced proteolysis [9]. Calpains are activated by increased
calcium ions in the cytoplasm [7]. We tested whether p38α MAP kinase is also involved in the regulation
of unloading-induced calpain-dependent proteolysis. VX-745 treatment blocked the increase in calpain-1
expression during unloading. These data suggest that calpain-1 inhibition by VX-745 treatment could
be involved in the observed in our experiments decrease of unloading-induced muscle atrophy.
The ubiquitin–proteasome pathway plays critical role in skeletal muscle atrophy. In our experiments,
VX-745 treatment prevented increase of the ubiquitin expression during unloading. Expression of
muscle-specific E3 ubiquitin ligases MAFbx and MuRF1 is activated shortly after unloading and peaks
at the third day [16,26]. VX-745 treatment prevented unloading-induced increase in MuRF-1, whereas
MAFbx expression was not affected. It was previously suggested that MuRF-1 and MAFbx could play
different roles in the atrophic process. MuRF-1 is mostly involved in the breakdown of myofibrillar
proteins [27], whereas MAFbx controls both the breakdown of cytoskeletal proteins as well as protein
synthesis [28].
It was previously reported that p38 regulates muscle atrophy [10]. The p38 MAP kinase family
has four members (α, β, γ, and δ), and this enables a large variety of responses when activated by
different extracellular signals. In particular, it was shown that p38β, but not p38α, is mediating muscle
catabolism by activation of C/EBPβ and upregulation of MAFbx [29]. In mice with muscle-specific
ablation of p38α MAP kinase, the expression of MuRF1 and MAFbx in fast muscle was significantly
lower than in wild-type mice [10]. This correlates well with our findings, suggesting that p38α MAPK
is involved in the regulation of MuRF-1 mRNA expression upon rat soleus muscle unloading.
Previous studies suggested that unloading-induced upregulation of MuRF1 and MAFbx expression
was controlled by the transcription factor FoxO [6]. The level of FoxO3 phosphorylation in our study
was reduced only in the HS group, but not in the HSVX group. This implies that changes in MuRF-1
expression in our study could be controlled by FoxO3. Our data correlate with previous studies, showing
that FoxO3 activity can be regulated via p38α MAP kinase signaling. For example, transcriptional
activity of FoxO3 was reduced in the muscle of mice with muscle-specific ablation of p38α MAP
kinase [10]. p38 MAP kinase signaling also regulates nuclear translocation and transcriptional activity
of FoxO3 in myoblasts [30]. It should be mentioned that, in addition to FoxO3, the expression of
MuRF1 and MAFbx can be regulated by other transcription factors. This regulation of expression
involves multiple mechanisms: phosphorylation, acetylation, and deacetylation. For example, when
HDAC 1, HDAC 4, and HDAC 5 were inhibited in unloaded skeletal muscle of rats, this resulted in
decreased expression of MAFbx, whereas MuRF1 expression was not changed [23]. Therefore, it is
possible that in our current study the expression of MuRF1 and MAFbx could have been similarly
regulated by multiple mechanisms. The role of Akt1 signaling as one of the key signaling pathways in
skeletal muscle atrophy is well documented [31,32]. During muscle unloading, Akt1 promotes protein
degradation through the mTOR and p70S6K pathways, induces expression of MuRF1 and MAFbx,
and downregulates protein synthesis via dephosphorylation of FoxO transcriptional factor. In our
experiments, Akt1 phosphorylation was decreased in both HS and HSVX groups. At the same time,
the level of FoxO3 phosphorylation was reduced only in the HS group, but not in the HSVX group.
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This observation implies that Akt1 signaling probably does not have a significant effect on the FoxO3
phosphorylation in the HSVX group.
Transcriptional coactivator PGC-1α also plays an important role during skeletal muscle atrophy [33].
It was reported that the level of PGC-1α expression was decreased after 3 days of skeletal muscle
unloading [18]. Upstream signaling pathways regulating PGC-1α expression are not well elucidated. It was
suggested that calcineurin A, CaMK, p38 MAPK, and AMPK pathways may be involved in the regulation of
PGC-1α [34–36]. In agreement with previous observations, our data also showed that unloading decreased
PGC-1α protein expression. Treatment with VX-745 inhibitor prevented unloading-induced decrease in
PGC-1α protein content. On the basis of these results, we conclude that p38α MAP kinase signaling is
important for the regulation of PGC-1α expression during unloading. PGC-1α overexpression decreases
expression of E3 ubiquitin ligases [18]. In our study, unloading-increased expression of MuRF1 E3 ubiquitin
ligase correlated with a decrease in PGC-1α protein content. Treatment with VX-745 inhibitor blocked
both MuRF1 increase and the decrease of PGC-1α protein content. This suggests that PGC-1α can be
involved in the regulation of MuRF1 expression during early stages of unloading-induced skeletal muscle
atrophy. PGC-1α expression is downregulated by IL-6 signaling [19]. Chronic IL-6 injections into skeletal
muscle results in muscle atrophy [37]. Muscle unloading increases IL-6 expression [33], whereas inhibiting
IL-6 during unloading diminishes MuRF1 activation without any effect on the MAFbx expression [38].
IL-6 expression in myotubes is regulated by p38 MAPK [39]. In our experiments, unloading increased
expression of IL-6 and IL-6 receptors, whereas treatment with VX-745 inhibitor blocked/diminished this
increase. This is consistent with previously published data. The unloading-induced decrease in PGC-1α
expression correlates with the increase in IL-6 expression, suggesting that IL-6 may be involved in the
regulation of PGC-1α expression in a p38α MAPK-dependent manner.
Protein synthesis offsets protein degradation and helps to maintain muscle mass during unloading.
Skeletal muscle protein synthesis is regulated by a number of signaling pathways, including eEF2,
p70S6k, and 4E-BP1 phosphorylation. Our previous studies showed increased p70S6k phosphorylation
during early staged of unloading [40]. Akt1 and p70S6k phosphorylation can be regulated by
rapamycin-sensitive mTORC1 signaling as well as by mTORC2-signaling pathway [41,42]. We showed
that p70S6k phosphorylation was increased by unloading, and inhibiting p38α MAP kinase had no
effect on this increase. We conclude that p38α MAP kinase is not involved in the regulation of p70S6k
phosphorylation at the early stages of unloading. The levels of total and phospho-4E-BP1 were not
changed in response to unloading and were not affected by the treatment with VX-745 inhibitor. It is
likely that 4E-BP1 and p70S6k phosphorylation in skeletal muscle is regulated via different signaling
pathways [43]. On the basis of these data, it is possible that 4E-BP1 phosphorylation did not play an
important role in muscle atrophy in our study.
It was previously reported that eEF2 phosphorylation suppresses eEF2 binding to the ribosome and
inhibits polypeptide chain growth [44]. eEF2 phosphorylation is regulated by calcium concentrations,
low pH value, activities of protein kinase A, and AMP-activated protein kinase [45–47], which leads to
the inhibition of elongation. In our experiments, eEF2 phosphorylation was increased by unloading
and was not regulated by the treatment with VX-745 inhibitor, whereas unloading-induced muscle
atrophy was blocked in the HSVX group. We conclude that eEF2 phosphorylation is not regulated by
p38α MAP kinase, and the preservation of muscle mass is not a result of improved protein elongation
or translation.
In summary, in our experiments inhibition of p38α MAP kinase using VX-745 inhibitor prevented
unloading-induced skeletal muscle atrophy. Muscle atrophy was mostly regulated by calpain-1 and E3
ubiquitin ligases, whereas protein translation and elongation were not crucially important. The current
study, for the first time, showed that p38α MAP kinase signaling regulates unloading-induced increase
in MuRF1, but not MAFbx expression. This regulation might involve IL-6 and PGC-1α as downstream
signaling molecules.
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4. Methods and Materials
4.1. Animal Procedures
The experiments were performed in compliance with the internationally accepted regulations and
rules of biomedical ethics. The study was approved by the Committee on Bioethics of the Russian
Academy of Sciences (protocol 481, 06/12/2018). All animal experiments were performed at the Institute
of Biomedical Problems, RAS, Russia. Animals were kept at 22 ◦C in a light-controlled environment
(12:12 h light–dark cycle) with water and food available ad libitum. Twenty-four male Wistar rats (3
months old, 180–200 g body weight range) were obtained from the certified Nursery for the Laboratory
Animals of the Institute of Bioorganic Chemistry of the Russian Academy of Sciences (Pushchino,
Moscow region). Rats were randomly assigned to one of the three groups with eight animals per group:
non-treated control (C), or three days of hindlimb suspension/unloading with (HSVX) or without (HS)
p38α inhibitor VX-745 (10 mg/kg/day orally with small amount of food soaked in VX-745 solution;
#A8686, APExBio, Houston, TX, USA). Care was taken to ensure that each rat consumed the entire
small piece of food provided with each treatment. It was reported previously that drug delivery
with food by voluntary ingestion might be a better option than stress-inducing gavage technique [48].
VX-745 (5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido [1 ,6-b] pyridazin-6-one) is
a highly potent (IC50 = 10 nM) inhibitor of p38α. VX-745 is also highly selective for p38α MAPK,
with 20-fold selectivity over p38β and 1000-fold selectivity over the closely related kinases ERK1 and
JNK1–3. The drug concentration was determined on the basis of the drug manufacturer’s protocol and
previously published data [49], as well as current human clinical trials for dementia and Alzheimer’s
disease (ClinicalTrials.gov). The control animals received equal amounts of food soaked in the vehicle
solution. At the end of the 3-day experiment, rats were euthanized by overdose of 10% avertin solution
(Sigma-Aldrich Corp., St. Louis, MO, USA) and soleus muscle was immediately dissected, weighed,
divided into aliquots, frozen in liquid nitrogen, and stored at -85◦C for the subsequent analyses.
4.2. Hindlimb Suspension Protocol
The tail-traction method of noninvasive tail-casting procedure was used for the hindlimb suspension,
as previously described [8]. Suspended animals were free to move around the cage using their forelimbs
to obtain food and water.
4.3. Protein Extraction and Western Blot Analysis
Total protein extracts were prepared from 50 mg of frozen soleus muscle. Complete Protease
Inhibitor Cocktail (#sc-29130, Santa Cruz Biotechnology, Dallas, TX, USA), Phosphatase Inhibitor
Cocktail B (#sc-45045, Santa Cruz Biotechnology, Dallas, TX„ USA), PMSF (1 mM), aprotinin (10 µg/mL),
leupeptin (10 µg/mL), and pepstatin A (10 µg/mL) were used to maintain extract integrity and function.
Quick Start Bradford Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA) was used to quantify
protein content. The samples were diluted in Laemmli buffer, run on 10% SDS-PAGE (20 µg/lane),
and transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA, USA). Membranes
were blocked with blocking buffer (5% nonfat milk powder, TBS pH 7.4, and 0.1% Tween-20) and
incubated overnight at 4◦C with the primary antibodies. We used primary antibodies against total
p38 MAPK (1:1000; #9212, Cell Signaling Technology, Danvers, MA, USA) and phosphorylated p38
MAPK (Thr180/Tyr182; 1:1000; GTX59567, GeneTex, Irvine, CA, USA), total Akt (1:1000; #2920, Cell
Signaling Technology, USA) and phosphorylated Akt (Ser 473; 1:1500, #4058, Cell Signaling Technology,
USA), phosphorylated eEF2 (Thr56; 1:1000; #2331, Cell Signaling Technology, Danvers, MA, USA),
total eEF2 (1:1000; #2332, Cell Signaling Technology, Danvers, MA, USA) and phosphorylated 4E-BP1
(Thr37/46; 1:1000; #2855, Cell Signaling Technology, Danvers, MA, USA), total 4E-BP1 (1:1000; #9452,
Cell Signaling Technology, Danvers, MA, USA), total FoxO3 (1:1000; #2497, Cell Signaling Technology,
Danvers, MA, USA) and phosphorylated FoxO3 (Ser 253; 1:1000; #sc-101683, Santa Cruz Biotechnology,
Dallas, TX, USA), PGC-1α (1:3000, ab54481, ABCAM, Cambridge, MA, USA USA), and MuRF-1 (1:500;
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#183094, ABCAM, Cambridge, MA, USA). Blots incubated with antibodies against GAPDH (1:10000,
#G041, Applied Biological Materials Inc., Richmond, BC, Canada) were used for the normalization
of loading. After three washes (10 minutes each) with TBS-Tween (TBS and 0.1% Tween-20), the
membranes were incubated for 1 hour at room temperature with horseradish peroxidase-conjugated
goat anti-rabbit (1:30,000, #111-035-003, Jackson Immuno Research, West Grove, PA, USA) or goat
anti-mouse (1:25,000, #5178-2504, Bio-Rad Laboratories, Hercules, CA, USA) secondary antibodies.
The membranes were washed again in TBS-Tween three times, incubated with Immun-Star HRP
(horseradish peroxidase) Chemiluminescent system (Bio-Rad Laboratories, Hercules, CA, USA). All
images were analyzed within the linear range. The protein bands were quantified using a C-DiGit Blot
Scanner (LI-COR Biotechnology, Lincoln, NE, USA) and Image Studio C-DiGit software. The control
and experimental samples were run on the same gel. Total protein staining (Ponceau S) was used
as loading controls (data not shown). GAPDH protein content used for the normalization was not
changed between the groups. The protein expression data for each group are expressed as a percentage
of the control group values.
4.4. RNA Isolation and Reverse Transcription
Total RNA was extracted from 10 mg of frozen soleus muscle samples using an RNeasy Micro
Kit (Qiagen, Hilden, Germany). RNA samples were treated with proteinase K and DNase I. RNA
concentration was evaluated using a UV 2450 spectrophotometer (Shimadzu, Japan). Isolated RNA in
aqueous solution was frozen at −85◦C for storage. Reverse transcription was performed by incubating
0.5 µg of RNA, random hexamers d(N)6, dNTPs, RNase inhibitor, and MMLV (Moloney Murine
Leukemia Virus) reverse transcriptase for 60 min at 42 ◦C.
4.5. Quantitative PCR Analysis
One microliter of cDNA was amplified in a 25 µL SYBR Green PCR reaction containing 1×
Quantitect SYBR Green Master Mix (Syntol, Moscow, Russia) and 10 pM of each forward and reverse
primer. Sequences of the primers used in the current study were as follows: forward 5′-CTACGAT
GTTGCAGCCAAGA-3′ and reverse 5′-GGCAGTCGAGAAGTCCAGTC-3′ for MAFbx; forward 5′-GC
CAATTTGGTGCTTTTTGT-3′ and reverse 5′-AAATTCAGTCCTCTCCCCGT-3′ for MuRF-1; forward
5′-CACCAAGAAGGTC AAACAGGA-3′ and reverse 5′-GCAAGAACTTTATTCAAAGTGCAA-3′
for ubiquitin, forward 5′-ACGGCAA GTTCAACGGCACAGTCAA-3′ and reverse 5′-GCTTTCCAG
AGGGGCCATCCACA-3′ for GAPDH; forward 5′ TCATGAAGTGTGACGTTGACATCC-3′ and reverse
5′-GTAAAACGCAGCTCAGTAACAGTC-3′ for β-actin.
The annealing temperature was set on the basis of the optimal annealing temperature of PCR
primers. The amplification was monitored in real-time using a iQ5 Multicolor Real-Time PCR Detection
System (Bio-Rad Laboratories, Hercules, CA, USA). To confirm the amplification specificity, PCR
products from each primer pair were subjected to a melting curve analysis. Relative quantification
was performed on the basis of the threshold cycle (CT value) for each PCR sample [50]. Initially, two
housekeeping genes were evaluated for normalization: GAPDH and β-actin. Normalization to the
level of expression of GAPDH and β-actin showed similar results (data not shown). GAPDH was
chosen for the normalization of all quantitative PCR analysis experiments in the current study.
4.6. Statistical Analysis
All PCR data are expressed as median and interquartile range (0.25–0.75). Statistical analysis was
performed using the REST 2009 v.2.0.12 (Qiagen, Hilden, Germany) and Origin Pro v.8.0 (OriginLab Corp.,
Northampton, MA, USA) programs. All Western blot data are expressed as means ± SE. Significant
differences between groups were statistically analyzed using two-way ANOVA followed by Tukey’s test.
When normality testing failed, data were analyzed by nonparametric methods (Kruskal–Wallis ANOVA
followed by Dunnett’s test). Differences with values of p < 0.05 were considered statistically significant.
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